Intra-Cellular Therapies (ITCI) Files Mixed Shelf

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Intra-Cellular Therapies (ITCI) Files Mixed Shelf

Intra-Cellular Therapies (ITCI) PT Raised to $91 at BofA Securities

April 17, 2024 5:13 AM EDT

BofA Securities analyst Jason Gerberry raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $91.00 (from $82.00) while maintaining a Buy rating.

The analyst comments "This morning, ITCI reported positive Ph3 topline results from its first MDD trial (Study 501) assessing Caplyta as an... More